and Springworks Therapeutics. According to TipRanks, Werber has an average return of 6.2% and a 47.62% success rate on recommended stocks. Septerna, Inc. has an analyst consensus of Hold ...

Joseph covers the Healthcare sector, focusing on stocks such as Monte Rosa Therapeutics, Rocket Pharmaceuticals, and Enanta Pharmaceuticals. Currently, the analyst consensus on Septerna ...

Septerna (NASDAQ:SEPN – Get Free Report) had its target price decreased by analysts at Wells Fargo & Company from $14.00 to $11.00 in a report released on Friday, MarketBeat Ratings reports.

March 27, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (SEPN) (Nasdaq: SEPN), a biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today provided a ...

Shares of Septerna, Inc. (SEPN) have gained 0.8% over the past four weeks to close the last trading session at $6.29, but there could still be a solid upside left in the stock if short-term price ...

Septerna, Inc. (Nasdaq: SEPN), a biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today provided a corporate overview complete with upcoming ...

REDWOOD CITY, Calif., April 8, 2025 /PRNewswire/ -- Synthego and Vita Therapeutics, Inc. today announced a licensing agreement to integrate Synthego's high-fidelity hfCas12Max CRISPR system into ...

March 27, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today provided a corporate overview ...

Septerna stock traded down $0.32 during mid-day trading on Friday, hitting $5.18. The stock had a trading volume of 19,683 shares, compared to its average volume of 457,900. The firm’s 50-day ...

Under the merger agreement, Channel will acquire 100% of Pelthos’ issued and outstanding equity interests, change its name to Pelthos Therapeutics, and trade on the NYSE American exchange under ...